Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent

Abstract In this study, ellagic acid (ELA), a skin anticancer drug, is capped on the surface(s) of functionalised graphene oxide (GO) nano‐sheets through electrostatic and π–π staking interactions. The prepared ELA‐GO nanocomposite have been thoroughly characterised by using eight techniques: Fourie...

Full description

Saved in:
Bibliographic Details
Main Authors: Samer Hasan Hussein‐Al‐Ali, Suha Mujahed Abudoleh, Mohd Zobir Hussein, Saifullah Bullo, Arul Palanisamy
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:IET Nanobiotechnology
Online Access:https://doi.org/10.1049/nbt2.12009
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849683050264264704
author Samer Hasan Hussein‐Al‐Ali
Suha Mujahed Abudoleh
Mohd Zobir Hussein
Saifullah Bullo
Arul Palanisamy
author_facet Samer Hasan Hussein‐Al‐Ali
Suha Mujahed Abudoleh
Mohd Zobir Hussein
Saifullah Bullo
Arul Palanisamy
author_sort Samer Hasan Hussein‐Al‐Ali
collection DOAJ
description Abstract In this study, ellagic acid (ELA), a skin anticancer drug, is capped on the surface(s) of functionalised graphene oxide (GO) nano‐sheets through electrostatic and π–π staking interactions. The prepared ELA‐GO nanocomposite have been thoroughly characterised by using eight techniques: Fourier‐transform infrared spectroscopy (FTIR), zeta potential, X‐ray diffraction (XRD), thermogravimetric analysis (TGA), Raman spectroscopy, atomic force microscopy (AFM) topographic imaging, transmission electron microscopy (TEM), and surface morphology via scanning electron microscopy (SEM). Furthermore, ELA drug loading and release behaviours from ELA‐GO nanocomposite were studied. The ELA‐GO nanocomposite has a uniform size distribution averaging 88 nm and high drug loading capacity of 30 wt.%. The in vitro drug release behaviour of ELA from the nanocomposite was investigated by UV–Vis spectrometry at a wavelength of λmax 257 nm. The data confirmed prolonged ELA release over 5000 min at physiological pH (7.4). Finally, the IC50 of this ELA‐GO nanocomposite was found to be 6.16 µg/ml against B16 cell line; ELA and GO did not show any cytotoxic effects up to 50 µg/ml on the same cell lines.
format Article
id doaj-art-d19f9de49dd747dca12e16327f822e9d
institution DOAJ
issn 1751-8741
1751-875X
language English
publishDate 2021-02-01
publisher Wiley
record_format Article
series IET Nanobiotechnology
spelling doaj-art-d19f9de49dd747dca12e16327f822e9d2025-08-20T03:24:00ZengWileyIET Nanobiotechnology1751-87411751-875X2021-02-01151798910.1049/nbt2.12009Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agentSamer Hasan Hussein‐Al‐Ali0Suha Mujahed Abudoleh1Mohd Zobir Hussein2Saifullah Bullo3Arul Palanisamy4Department of Chemistry Faculty of Science Isra University Amman JordanFaculty of Pharmacy Isra University Amman JordanMaterials Synthesis and Characterization Laboratory Institute of Advanced Technology (ITMA) University Putra Malaysia Selangor MalaysiaMaterials Synthesis and Characterization Laboratory Institute of Advanced Technology (ITMA) University Putra Malaysia Selangor MalaysiaLaboratory of Vaccines and Immunotherapeutics Institute of Bioscience University Putra Malaysia Selangor MalaysiaAbstract In this study, ellagic acid (ELA), a skin anticancer drug, is capped on the surface(s) of functionalised graphene oxide (GO) nano‐sheets through electrostatic and π–π staking interactions. The prepared ELA‐GO nanocomposite have been thoroughly characterised by using eight techniques: Fourier‐transform infrared spectroscopy (FTIR), zeta potential, X‐ray diffraction (XRD), thermogravimetric analysis (TGA), Raman spectroscopy, atomic force microscopy (AFM) topographic imaging, transmission electron microscopy (TEM), and surface morphology via scanning electron microscopy (SEM). Furthermore, ELA drug loading and release behaviours from ELA‐GO nanocomposite were studied. The ELA‐GO nanocomposite has a uniform size distribution averaging 88 nm and high drug loading capacity of 30 wt.%. The in vitro drug release behaviour of ELA from the nanocomposite was investigated by UV–Vis spectrometry at a wavelength of λmax 257 nm. The data confirmed prolonged ELA release over 5000 min at physiological pH (7.4). Finally, the IC50 of this ELA‐GO nanocomposite was found to be 6.16 µg/ml against B16 cell line; ELA and GO did not show any cytotoxic effects up to 50 µg/ml on the same cell lines.https://doi.org/10.1049/nbt2.12009
spellingShingle Samer Hasan Hussein‐Al‐Ali
Suha Mujahed Abudoleh
Mohd Zobir Hussein
Saifullah Bullo
Arul Palanisamy
Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
IET Nanobiotechnology
title Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
title_full Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
title_fullStr Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
title_full_unstemmed Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
title_short Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent
title_sort graphene oxide ellagic acid nanocomposite as effective anticancer and antimicrobial agent
url https://doi.org/10.1049/nbt2.12009
work_keys_str_mv AT samerhasanhusseinalali grapheneoxideellagicacidnanocompositeaseffectiveanticancerandantimicrobialagent
AT suhamujahedabudoleh grapheneoxideellagicacidnanocompositeaseffectiveanticancerandantimicrobialagent
AT mohdzobirhussein grapheneoxideellagicacidnanocompositeaseffectiveanticancerandantimicrobialagent
AT saifullahbullo grapheneoxideellagicacidnanocompositeaseffectiveanticancerandantimicrobialagent
AT arulpalanisamy grapheneoxideellagicacidnanocompositeaseffectiveanticancerandantimicrobialagent